Therapy

Recognizing the rapid progress and growing importance of therapeutic applications in nuclear medicine, the Nuclear Medicine Europe Therapy Working Group was established to represent this evolving, cutting-edge sector and to highlight the leading role of all players in the industrial value chain of radiopharmaceutical production for the benefit of patients.

The mission of the Therapy Working Group is based on four fundamental pillars:

1. Support the nuclear medicine industry in delivering innovative therapeutic solutions to healthcare professionals and patients
2. Establish radioligand therapy (RLT) as a key component among anti-cancer therapies
3. Promote equal patient access to the medical benefits of RLT across Europe
4. Make RLT affordable through cost-efficient use of medical resources
   
   

To achieve this mission, the Therapy Working Group welcomes and includes members from companies representing the different actors in the value chain that contribute to bringing the full medical benefit of radiopharmaceuticals to patients. This approach maximizes the expertise developed within our industry.

The Therapy Working Group serves as a reference group for Nuclear Medicine Europe Executive Committee decisions and actions. The working group develops opinions and positions on therapeutic perspectives and works to ensure that these positions are well recognized and incorporated into key policy documents at both EU and national levels.

When necessary, the Therapy Working Group meets with other working groups to discuss issues of shared relevance and foster synergistic activities.